Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 25, 2019

View Archived Issues

GABA Therapeutics and ATAI Life Sciences to develop GRX-917 for the treatment of mood disorders

Senolytics work as advertised

European Commission approves Epidyolex for the treatment of LGS and Dravet syndrome

Ovid announces positive initial data from ongoing ENDYMION extension trial of soticlestat

Phase III study of StrataGraft regenerative tissue meets both primary endpoints

PhoenixMD receives FDA clearance to initiate phase I/Ib study of PMD-026

Positive topline results presented from phase II STAR study of tolperisone

Nanobiotix presents phase I data from phase I/II study of NBTXR-3 in HCC

Phase I study of the oncolytic virus DNX-2401 in diffuse intrinsic pontine glioma

Trabectedin does not improve PFS and OS compared to standard of care in patients with meningioma

CRISPR/Cas9-mediated editing of hepatic G6pc as new model of glycogen storage disease type 1

Discovery of a novel 5-miRNA biomarker panel for early detection of NSCLC

New approach prevents GvHD, unintended consequences

Psoriasis drugs may be repurposed to treat osteosarcoma

Cytokines found to be prognostic in stage IA lung adenocarcinoma

Synthesis and evaluation of a novel radiolabeled peptide targeting GnRH receptor for prostate cancer

Novel mouse model of pancreatic cancer-induced cachexia mimicking human features

Bristol-Myers Squibb patents FPR1 and FPR2 agonists

Novartis patent details HBsAg secretion inhibitors

Inflazome reports new NLRP3 inflammasome inhibitors

Reaction Biology prepares and tests HDAC inhibitors

Pediatric phase III trial of dasiglucagon for severe hypoglycemia meets primary endpoint

Constellation begins phase I/II trial of CPI-0209 in advanced solid tumors

Incyte identifies PI3Kgamma inhibitors

FDA clears Linnaeus' IND for phase I/II trial of LNS-8801 in advanced cancer

FDA accepts Tarsius' IND for TRS-01 for ocular diseases

European Commission approves Vitrakvi for solid tumors with NTRK gene fusion

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.